B

Bio Protocol

Decentralized biotech funding via IP NFTs

Overview

PsyDAO is a decentralized biotech protocol that creates a marketplace for research and an IP NFT framework. It funds biotech projects—particularly in cryopreservation—by offering up to $100,000 per project and connecting academics, biotech companies, investors, and patients in a fully governance-driven community. Powered by Molecule, PsyDAO reviews applications for new cohorts and supports DAO founders with a network of experienced contributors, enabling direct ownership and control of research IP through IP NFTs. Unlike traditional funding models, PsyDAO blends DeSci principles with an open-source ethos, allowing patients, researchers, and investors to govern and benefit from research outcomes. Its goal is to accelerate biotech research by providing rapid, community-governed funding and a novel IP framework that unlocks data access and legal rights for research.

Work here?Claim your company

About Bio Protocol

Simplify's Rating
Why Bio Protocol is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Enterprise SoftwareCrypto & Web3Biotechnology

Company Size

11-50

Company Stage

Seed

Total Funding

$71.3M

Headquarters

Nantes, France

Founded

2022

Get referred to Bio Protocol

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • OpenLabs launched June 19, 2026, and the ecosystem surpassed $33 million raised.
  • NeuroLab’s September 2026 Ignition Sale closed 2.2x oversubscribed with 442,646 USDC.
  • Credit-card Launchpad funding via Privy lowers onboarding friction for non-crypto biotech backers.

What critics are saying

  • BIO traded near $0.0189 on November 14, 2026, down 74% yearly.
  • The October 1, 2026 mandatory vesting change followed NeuroLab advisor sell-off damage.
  • Tokenized IP sales invite SEC scrutiny, threatening Launchpad launches and exchange liquidity.

What makes Bio Protocol unique

  • Bio Protocol bundles OpenLabs, Launchpad, and onchain IP into one DeSci funding stack.
  • The September 2026 Open Science Index cataloged 6,720 resources, sharpening researcher discovery.
  • BIO’s January 2026 AI scientist, BIOS, coordinates literature search and computational analysis.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$71.3M

Above

Industry Average

Funded Over

2 Rounds

Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Above Average

Industry standards

$3.3M
$2M
$2.3M
$3M
$6.9M

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Company Equity

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 22nd, 2026
AI slashes drug discovery to 24 hours and $1,500 at DeSci platform Bio Protocol

Bio Protocol CEO announced his team used AI to design a novel ADHD drug candidate in roughly 24 hours. The AI scientist, PeptAI, ran simulated testing and priced initial physical lab validation at $1,000 to $1,500, compared to millions and years in traditional pharma. This cost collapse enables decentralised science (DeSci) funding models to support research through entire discovery phases. Bio Protocol, a token-governed platform routing capital to research DAOs, has become central to this shift by combining community funding with "agentic science". The company released BIOS in January, an AI scientist coordinating specialised agents for literature search and computational analysis. However, Bio Protocol acknowledges three structural problems remain on the path from candidate to approved drug, even with AI-enabled discovery and community fundraising combined.

Gate.com
Sep 20th, 2025
dValueChain v.1.0 Launch

Bio Protocol is set to roll out dValueChain v.1.0 in the first quarter.

Cointelegraph
Sep 18th, 2025
Maelstrom, Animoca back Bio Protocol's bid to unite AI, biotech, crypto

Bio Protocol secured $6.9 million in funding from Maelstrom Fund, Animoca Brands and other investors to advance science using AI and crypto.

The Block
Sep 17th, 2025
BIO Protocol raises $6.9M seed funding

Bio Protocol has secured $7 million in seed funding, led by Arthur Hayes' Maelstrom Fund. The decentralized science protocol aims to develop "scientific superintelligence" onchain using BioAgents.

Tech.eu
Jan 23rd, 2025
How Molecule Is Accelerating Medical Research Through Tokenised Ip And Decentralised Biotech Funding

Academic research is challenging. Obtaining grants and financial support for research projects is highly competitive and time-consuming. Researchers typically juggle multiple projects, including teaching, and they also have to deal with realities like data management and ethics.But now, a movement called Decentralised Science (DeSci) aims to transform traditional scientific research by connecting patients, scientists, investors, biotech DAOs, and novel crowdfunding methods. It democratises access to research funding through greater transparency, open access, and collaborative efforts, thus accelerating scientific breakthroughs.DeSci leverages blockchain-based platforms, tools, NFTs, tokens, decentralised autonomous organisations (DAOs), and Web3 principles to facilitate funding for scientific research.From online communities to open source bioscienceI spoke to a pioneer of the DeSci movement, Paul Kohlhaas, founder and Chief Architect at Molecule, a platform dedicated to accelerating scientific research and bringing intellectual property onchain through community-driven initiatives. It's like crowdfunding on steroids, where instead of getting an item in exchange for your funding, you get a cut of the intellectual property (IP).Kohlhaas spent his youth engaging with online biohacking forums and patient communities on platforms like Reddit, where online communities focused on tackling medical challenges—like diabetic patients collaborating to develop their own insulin due to its prohibitive cost in the US. From HIV communities exploring gene therapies to cancer patient groups sharing experimental treatments, nootropics and longevity, there was a community for virtually everything.He recalls:"What struck me was the collaborative and open spirit of these groups

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Bio Protocol right now.

Find jobs on Simplify and start your career today

We update Bio Protocol's jobs every few hours, so check again soon!Browse all jobs